Intercostal nerve cryoablation reduces inpatient opioid consumption by 102 morphine milligram equivalentsCryoablation reduces opioid use after thoracic and cardiac surgery

This systematic review and meta-analysis evaluated the impact of intercostal nerve cryoablation (INC) on opioid consumption and hospital outcomes in patients undergoing major thoracic and cardiac surgeries. The study population included 18,465 patients who underwent non-pectus repair procedures, including surgical stabilization of rib fractures, thoracotomy, pulmonary resections, lung transplants, aortic aneurysm repair, and various other cardiac procedures. This large sample size provides a broad overview of the clinical impact of INC in high-intensity thoracic and cardiac environments.

The primary intervention was intercostal nerve cryoablation (INC), which was compared against the standard of care (SOC) without INC. The study specifically aimed to measure changes in opioid consumption as a primary outcome, while secondary outcomes included the total hospital length of stay (LOS).

Regarding the primary outcome, patients who received intercostal nerve cryoablation showed a significant reduction in inpatient opioid consumption compared to those receiving standard care. Specifically, there was a reduction of 102 morphine milligram equivalents (MME) with a 95% CI of -180.00 to -23.87. This indicates a statistically significant decrease in the amount of opioids administered during the hospital stay for patients undergoing these procedures.

Secondary outcomes provided mixed results regarding post-discharge care and recovery duration. For opioid consumption after discharge, the study reported an absolute reduction of 89 morphine milligram equivalents (MME), but this result was not statistically significant with a 95% CI of -182.00 to 4.56. Furthermore, there was no significant difference reported in the hospital stay duration for patients receiving INC compared to those receiving standard care.

Safety and tolerability data were not reported in the provided evidence. Consequently, specific adverse event rates, serious complications, or discontinuation rates due to intolerance are unknown from this analysis.

These results contribute to the evolving landscape of multimodal analgesia in thoracic and cardiac surgery. While other interventions like ERAS protocols have been shown to potentially reduce opioid use and shorten stays in different surgical contexts (such as orthognathic surgery), this meta-analysis specifically highlights INC as a targeted intervention for reducing inpatient opioid requirements.

Methodological limitations were not reported, but the distinction between significant inpatient reduction and non-significant post-discharge reduction is a key nuance for clinical interpretation. The lack of reported safety data means that while the efficacy regarding opioid reduction is clear, the full risk-benefit profile of INC remains partially obscured by missing data.

Clinically, these results suggest that intercostal nerve cryoablation may be an effective strategy to reduce the volume of opioids administered during the immediate postoperative period for patients undergoing thoracic and cardiac surgeries. This could potentially improve patient comfort and safety regarding opioid-related side effects during the hospital stay.

Several questions remain unanswered, most notably the specific safety profile of INC and whether it leads to a reduction in pain scores or other subjective measures of discomfort. Additionally, further research is needed to determine if there is any long-term impact on pain management for these patients beyond the initial inpatient period.